Novo Nordisk has agreed to distribute its Ozempic and all forms of its Wegovy semaglutide weight-loss drugs—injectable and pill—through Hims & Hers’ telehealth platform, giving Hims users direct access to FDA-approved medicines once clinically appropriate.

The agreement resolves a months-long dispute over Hims’ attempt to sell compounded GLP-1 copies, with Novo Nordisk dropping its lawsuit and Hims ceasing all advertising and distribution of unapproved analogues to comply with patent protections.

The expanded distribution channel could boost U.S. sales of semaglutide products by tapping Hims’ customer base, and Novo Nordisk shares rose roughly 2% on the announcement, reflecting investor optimism about improved market reach.